S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:LYRA

Lyra Therapeutics (LYRA) Stock Price, News & Analysis

$6.53
+0.40 (+6.53%)
(As of 03/27/2024 ET)
Today's Range
$6.16
$6.79
50-Day Range
$4.55
$6.53
52-Week Range
$1.89
$6.79
Volume
871,452 shs
Average Volume
334,846 shs
Market Capitalization
$390.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.67

Lyra Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
94.0% Upside
$12.67 Price Target
Short Interest
Healthy
0.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Lyra Therapeutics in the last 14 days
Based on 18 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.06) to ($1.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.44 out of 5 stars

Medical Sector

509th out of 939 stocks

Surgical & Medical Instruments Industry

58th out of 99 stocks

LYRA stock logo

About Lyra Therapeutics Stock (NASDAQ:LYRA)

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

LYRA Stock Price History

LYRA Stock News Headlines

my top trade on these 9 tickers
This indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
LYRA Jul 2024 2.500 call
LYRA Jul 2024 7.500 call
LYRA Apr 2024 7.500 put
LYRA May 2024 7.500 call
15 Unhappiest States in the US
Lyra Therapeutics Insider Ups Holding By 11% During Year
See More Headlines
Receive LYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:LYRA
Fax
N/A
Employees
78
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.67
High Stock Price Target
$15.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+94.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-62,680,000.00
Net Margins
-4,023.11%
Pretax Margin
-4,019.32%

Debt

Sales & Book Value

Annual Sales
$1.56 million
Book Value
$2.54 per share

Miscellaneous

Free Float
43,407,000
Market Cap
$390.10 million
Optionable
Optionable
Beta
0.20
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Harlan W. Waksal M.D. (Age 71)
    Executive Chairman
    Comp: $214.06k
  • Dr. Maria Palasis Ph.D. (Age 59)
    CEO, President & Director
    Comp: $865.15k
  • Dr. Richard Nieman M.D. (Age 61)
    Chief Medical Officer
    Comp: $606.7k
  • Dr. Carmichael S. Roberts Jr. (Age 56)
    Ph.D., Co-Founder
  • Mr. Jason Cavalier (Age 51)
    CFO, Treasurer & Secretary
    Comp: $464.11k
  • Mr. Ray Knox
    Vice President of Operations
  • Dr. John E. Bishop Ph.D. (Age 62)
    Chief Technology Officer
  • Ms. Ellen Cavaleri
    Senior Vice President of Investor Relations & Communications
  • Mr. Ronan P. O'Brien J.D. (Age 51)
    Chief Legal Officer
  • Ms. Corinne Noyes (Age 56)
    Senior Vice President of Commercial Strategy & Market Development
    Comp: $426.73k

LYRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Lyra Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LYRA shares.
View LYRA analyst ratings
or view top-rated stocks.

What is Lyra Therapeutics' stock price target for 2024?

4 Wall Street research analysts have issued 1 year price objectives for Lyra Therapeutics' shares. Their LYRA share price targets range from $11.00 to $15.00. On average, they predict the company's stock price to reach $12.67 in the next twelve months. This suggests a possible upside of 94.0% from the stock's current price.
View analysts price targets for LYRA
or view top-rated stocks among Wall Street analysts.

How have LYRA shares performed in 2024?

Lyra Therapeutics' stock was trading at $5.24 at the beginning of 2024. Since then, LYRA shares have increased by 24.6% and is now trading at $6.53.
View the best growth stocks for 2024 here
.

Are investors shorting Lyra Therapeutics?

Lyra Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 206,300 shares, an increase of 28.8% from the February 29th total of 160,200 shares. Based on an average daily trading volume, of 271,900 shares, the short-interest ratio is currently 0.8 days.
View Lyra Therapeutics' Short Interest
.

When is Lyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our LYRA earnings forecast
.

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) announced its earnings results on Tuesday, November, 9th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by $0.07. The business earned $0.01 million during the quarter. Lyra Therapeutics had a negative trailing twelve-month return on equity of 72.62% and a negative net margin of 4,023.11%. During the same period in the prior year, the firm posted ($0.49) earnings per share.

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE).

When did Lyra Therapeutics IPO?

Lyra Therapeutics (LYRA) raised $52 million in an IPO on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager.

Who are Lyra Therapeutics' major shareholders?

Lyra Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vestal Point Capital LP (5.71%), Point72 Asset Management L.P. (5.71%), Armistice Capital LLC (2.07%), Vanguard Group Inc. (2.04%), Vanguard Group Inc. (2.04%) and Parkman Healthcare Partners LLC (1.44%). Insiders that own company stock include C Ann Merrifield, Edward T Anderson, Harlan Waksal, Mukesh Mehta, Nbvm Gp, Llc and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Lyra Therapeutics?

Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LYRA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners